Doing a Roth Conversion in 2026? Beware This Pitfall.

Roth conversions move funds from traditional retirement accounts to Roth accounts, triggering taxable income that can push taxpayers above IRMAA thresholds and therefore increase Medicare Part B and D premiums two years later. The article notes the IRMAA MAGI cutoffs of $109,000 for single filers and $218,000 for married filers, and recommends staggering conversions and consulting a tax professional to minimize taxes and avoid Medicare surcharges, while highlighting Roth benefits (tax-free growth and no required minimum distributions).

Analysis

Market structure: The IRMAA thresholds ($109k single / $218k married MAGI) create a clear economic cliff that makes tax-timing behavioral shifts predictable. Winners: tax software/providers (INTU, HRB) and fee-based wealth managers (BLK, TROW) who capture demand for staged Roth conversions; Medicare Advantage/private payors (UNH, HUM, CVS) could see incremental MA enrollment if traditional Medicare becomes relatively more expensive. Losers: discretionary spending tied to older cohorts (certain retail/travel names) as higher IRMAA outlays reduce disposable income by $1k–$5k/yr for affected households.

Risk assessment: Tail risks include rapid legislative change (Congress or CMS adjusting IRMAA indexing) or IRS guidance that narrows allowable conversion timing — both could wipe out short-term revenue ramps; operational risk at custodians could trigger penalties and reputational damage. Timeline: immediate (weeks): spike in tax-software activity; short-term (3–12 months): advisor revenue and MA enrollment trends; long-term (2–5 years): portfolio asset allocation shifts as more savings sit in Roth tax-free envelopes, reducing future taxable distribution supply.

Trade implications: Direct plays: small tactical long in INTU/HRB into tax season (3 months) to capture conversion-planning volumes; medium-term (12–36 months) overweight UNH/HUM/CVS to capture MA uptake and ancillary Rx margins. Pair trades: long UNH vs short XLY exposure to older-consumer discretionary names (e.g., GPS) to express relative rerouting of retiree spend. Options: buy 9–18 month call spreads on UNH/INTU to limit downside while leveraging upside from enrollment and tax-season beats.

Contrarian angles: Consensus underestimates MA upside—if even 1–3% of traditional Medicare enrollees shift to MA over 3 years, revenue upside for top payors is material (mid-single-digit EPS lift). The market may overprice tax-software gains into INTU; small boutique tax advisers and custodians (not yet bid up) could be acquisition targets — watch M&A flow. Unintended consequence: a large coordinated conversion wave could temporarily boost Treasury issuance demand (tax payments) and tighten short-term funding dynamics.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long position in Intuit (INTU) and H&R Block (HRB) ahead of tax season (next 3 months) to capture elevated Roth-conversion planning volumes; hedge with a 6–9 month 10–15% OTM put to limit downside.
• Overweight UnitedHealth (UNH) and Humana (HUM) with a combined 3–4% position sized for 12–36 months to play potential Medicare Advantage inflows if IRMAA makes traditional Medicare relatively costlier; supplement with 18-month call spreads (buy 1, sell 1) to cap cost.
• Initiate a relative-value pair: long 1.5% UNH vs short 1.5% consumer-discretionary ETF XLY (or a specific older-skew retailer) for 6–18 months to express shift of retiree dollars from discretionary spend into healthcare premiums/MA enrollment.
• Reduce outright exposure by 1–2% to equities with heavy 65+ customer concentration (travel, certain retail) over 3–12 months; redeploy proceeds into tax-advisory/asset-manager names (BLK, TROW) and defensive healthcare names (CVS) to capture reallocation risk.
• Monitor CMS and SSA IRMAA guidance and congressional tax-policy proposals on a 30–90 day cadence; if thresholds are proposed to rise >5% or legislative repeal is signaled, close conversion-sensitive longs (INTU/HRB) and reallocate to consumer cyclicals within 2 weeks.